EFG International AG Invests $45.44 Million in McKesson Corporation $MCK

EFG International AG purchased a new stake in McKesson Corporation (NYSE:MCK) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 60,135 shares of the company’s stock, valued at approximately $45,443,000. McKesson accounts for about 0.8% of EFG International AG’s holdings, making the stock its 28th biggest holding.

Other institutional investors have also recently modified their holdings of the company. University of Texas Texas AM Investment Management Co. purchased a new position in McKesson in the fourth quarter worth $25,000. Swiss RE Ltd. purchased a new stake in shares of McKesson during the 4th quarter worth $26,000. Delos Wealth Advisors LLC purchased a new stake in shares of McKesson during the 2nd quarter worth $27,000. State of Wyoming acquired a new position in shares of McKesson during the 2nd quarter worth $29,000. Finally, Kingdom Financial Group LLC. acquired a new position in shares of McKesson during the 4th quarter worth $33,000. 85.07% of the stock is currently owned by hedge funds and other institutional investors.

More McKesson News

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson agreed to acquire Precision Medicine Group for approximately $2.25 billion. The transaction would add clinical research, consulting and biopharma commercialization capabilities to McKesson’s oncology-focused business, broadening its exposure to higher-growth healthcare services. Reuters article about McKesson’s Precision Medicine acquisition
• Positive Sentiment: McKesson raised its fiscal 2027 earnings outlook as oncology demand, GLP-1 volumes and specialty pharmaceutical distribution accelerate. The higher guidance reinforces expectations for double-digit earnings growth and supports investor confidence in the company’s growth strategy. McKesson FY2027 guidance article
• Positive Sentiment: Short interest fell 33% to about 2.42 million shares as of August 14, representing roughly 2.1% of shares outstanding and 2.2 days of average trading volume. The decline suggests reduced bearish positioning and may provide additional support for the stock.
• Neutral Sentiment: Healthcare stocks broadly advanced late Tuesday, giving McKesson a favorable sector backdrop. However, sector-wide gains do not necessarily reflect company-specific fundamentals. Healthcare sector update
• Negative Sentiment: Analysts caution that McKesson’s premium valuation leaves less room for execution setbacks. Drug-pricing pressure, potential policy changes and cash-flow demands associated with expansion and acquisitions remain risks to the investment thesis. McKesson valuation analysis

McKesson Stock Up 3.5%

Shares of NYSE MCK opened at $904.31 on Wednesday. The stock has a market capitalization of $105.43 billion, a PE ratio of 24.20, a P/E/G ratio of 1.72 and a beta of 0.30. The firm has a fifty day moving average of $825.22 and a 200-day moving average of $844.60. McKesson Corporation has a 52-week low of $673.38 and a 52-week high of $999.00.

McKesson (NYSE:MCK) last issued its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping the consensus estimate of $9.56 by $0.37. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The business had revenue of $105.38 billion for the quarter, compared to analyst estimates of $103.88 billion. During the same period last year, the company posted $8.26 EPS. The business’s quarterly revenue was up 7.7% on a year-over-year basis. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Equities research analysts expect that McKesson Corporation will post 44.65 EPS for the current fiscal year.

McKesson Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 1st. This is an increase from McKesson’s previous quarterly dividend of $0.82. McKesson’s dividend payout ratio (DPR) is presently 8.78%.

Insider Transactions at McKesson

In other McKesson news, Director Bradley E. Lerman sold 301 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $892.33, for a total transaction of $268,591.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Brian S. Tyler sold 8,463 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the completion of the sale, the chief executive officer directly owned 5,919 shares of the company’s stock, valued at $4,697,081.64. The trade was a 58.84% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 23,111 shares of company stock worth $18,011,274 over the last 90 days. Company insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on MCK shares. Evercore reiterated an “outperform” rating on shares of McKesson in a report on Thursday, August 6th. Wells Fargo & Company raised their target price on shares of McKesson from $812.00 to $933.00 and gave the stock an “equal weight” rating in a research report on Tuesday, August 11th. Wall Street Zen cut shares of McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $875.00 price target on shares of McKesson in a report on Friday, May 8th. Finally, Morgan Stanley reissued an “overweight” rating on shares of McKesson in a research note on Friday, August 7th. Fourteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $973.44.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.